Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

Oveporexton significantly improves wakefulness, sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, with reductions up to 88.8% in cataplexy rate.

• Why it matters: Narcolepsy type 1 causes debilitating symptoms like excessive sleepiness and cataplexy, and current treatments have limited effectiveness, highlighting the need for better therapies.
• What they did: Two phase 3 trials involving 273 participants tested twice-daily oveporexton (1 mg or 2 mg) versus placebo, measuring sleep latency, sleepiness, and cataplexy over 12 weeks.
• The result: Oveporexton markedly improved wakefulness and reduced sleepiness and cataplexy, though common side effects included increased urinary frequency and transient insomnia, supporting its potential as a treatment option.